“Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey”, FE, vol. 15, no. 2, pp. 39–44, Jun. 2014, doi: 10.7175/fe.v15i2.924.